Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | WDR5 | P61964 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501620 | 0.82 | MYC (0.50) | MYCWDR5HPGDKDM4EALDH1A1 | |
| SCHEMBL3499091 | 0.78 | ALDH1A1 (0.50) | HPGDKDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL13256303 | 0.76 | LIMK1 (0.46) | HPGDKDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL4753611 | 0.75 | GPBAR1 (0.39) | MYCWDR5HPGDKDM4EALDH1A1 | |
| SCHEMBL5577941 | 0.75 | HSD11B1 (0.40) | MYCWDR5HPGDKDM4EALDH1A1 | |
| SCHEMBL13256300 | 0.74 | MEN1 (0.53) | ALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL3498262 | 0.73 | TGFBR1 (0.46) | KDM4EHSD17B10SMN1; SMN2NPC1ALPL | |
| SCHEMBL5577966 | 0.73 | HSD11B1 (0.35) | MYCWDR5HPGDKDM4EALDH1A1 | |
| SCHEMBL13256307 | 0.73 | LIMK1 (0.49) | MYCWDR5HPGDKDM4EALDH1A1 | |
| SCHEMBL13256188 | 0.72 | MEN1 (0.48) | HPGDKDM4EALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7473783-B2 | Bicyclic pyrazolo protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1713814-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050176786-A1 | Bicyclic pyrazolo protein kinase modulators | STRUCTURAL GENOMIX (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005068473-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | MAP3K20, MAP4K2, MAP4K3 | MYC 764/4885WDR5 1623/4885HPGD 2895/4885 |
| US-20050176786-A1 | Bicyclic pyrazolo protein kinase modulators | MAP3K20, MAP4K2, MAP4K3 | MYC 764/4885WDR5 1623/4885HPGD 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.